How can a technical fix in legislation that costs the federal government nothing be smeared as an "earmark?"
When it will restore three million low-income and college women’s ability to access affordable birth control.
Sen. Jim DeMint (R-SC) is attacking a cost-neutral provision in the
omnibus appropriations bill that would restore the ability of pharmaceutical
companies to offer nominally priced drugs to college and university
health centers and family planning clinics. Clinics and university
health centers had done so for years before the Deficit Reduction Act
enacted in 2007 inadvertently left them unable to do so.
DeMint’s amendment calls the provision a "funding earmark for Planned
Parenthood Federation of America." First, it’s not an earmark. Second,
it enables college and university health centers, in addition to
providers like Planned Parenthood who work with low-income women, to
distribute birth control more cheaply.
Appreciate our work?
Rewire is a non-profit independent media publication. Your tax-deductible contribution helps support our research, reporting, and analysis.
Does DeMint care about the government’s money, or does he care about withholding from low-income and college women the ability to prevent pregnancies they don’t want?